No. | Age (yr)/Sex | Primary Tumor (grade) No. | RT and Timing (mo completed prior to imaging) | Chemotherapy |
---|---|---|---|---|
1 | 31/M | AA | 60 Gy 3D-C (9) | T-RT |
(III) | 25 Gy IMRT (2) | |||
2 | 58/M | GBM | 54 Gy 3D-C (22) | T-RT |
(IV) | 12 Gy GK (5) | |||
3 | 36/M | GBM | 60 Gy IMRT (3) | T-RT |
(IV) | ||||
4 | 56/M | GBM | 60 Gy IMRT (23) | T-RT |
(IV) | 30 Gy IMRT (10) | |||
5 | 45/F | GBM | 60 Gy 3D-C (26) | T-RT |
(IV) | ||||
6 | 44/M | GBM | 59.4 Gy IMRT (12) | T-RT |
(IV) | ||||
7 | 50/M | GBM | 37.5 Gy whole-brain RT (8) | T-RT |
(IV) | 30 Gy IMRT (5) | |||
8 | 42/M | GBM (DD-IV) | 60 Gy IMRT (60) | T-RT |
9 | 59/M | GBM | 59.4 Gy IMRT (13) | T-RT |
(IV) | ||||
10 | 60/F | Ana. ODG | 10 Gy GK (12) | T-RT |
(III) | ||||
11 | 54/M | AA | 59.4 Gy IMRT (11) | T-RT |
(III) | ||||
12 | 38/M | Ana. GG | 54 Gy IMRT (24) | T-RT |
(III) | 12 Gy GK (11) | |||
13 | 50/M | GBM (IV) | 60 Gy IMRT (1) | T-RT |
14 | 42/M | Ana. OA | 59.4 Gy IMRT (29) | T-RT |
(DD-III) | ||||
15 | 25/M | AA | None | None |
(DD-III) | ||||
16 | 48/F | OA | 59.4 Gy 3D-C (76) | T-RT |
(III) | ||||
17 | 53/M | Ana. ODG | None | None |
(DD-III) | ||||
18 | 62/F | GBM | 60 Gy 3D-C (8) | T-RT |
(IV) | 12 Gy GK (7) | |||
19 | 25/M | GBM | 60 Gy 3D-C (19) | T-RT & B |
(IV) | ||||
20 | 46/F | Ana. ODG | None | None |
(DD-III) | ||||
21 | 40/F | AA | None | None |
(III) | ||||
22 | 49/M | AA | None | None |
(DD-III) | ||||
23 | 73/F | GBM | 34 Gy IMRT (1) | T-RT |
(IV) | ||||
24 | 34/M | AA | None | None |
(DD-III) |
Note:—AA indicates anaplastic astrocytoma; Ana. GG, anaplastic ganglioglioma; Ana. ODG, anaplastic oligodendroglioma; Ana. OA, anaplastic oligoastrocytoma; DD = dedifferentiated from previous low-grade tumor; IMRT, intensity-modulated radiation therapy; GK, gamma knife; 3D-C, 3D conformal; T-RT, temodar (with initial radiation therapy); B, prior bevacizumab therapy; RT, radiation therapy.
All patients underwent prior surgical treatment for their primary tumors.